Disclosure Of First-Time Adoption [Text Block]

Egetis Therapeutics - Filing #5995613

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
Disclosure of first-time adoption [text block]
Disclosure of comparative information prepared under previous GAAP [text block]
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity
1 610,1 SEK
204,000,000 SEK
248,000,000 SEK
2 057,7 SEK
4,929,000,000 SEK
5,456,000,000 SEK
1 266,5 SEK
167,000,000 SEK
154,000,000 SEK
1 780,0 SEK
5,062,000,000 SEK
61,000,000 SEK
9,396,000,000 SEK
113,000,000 SEK
1 428,4 SEK
Comprehensive income
- SEK
- SEK
3,435,000,000 SEK
3,435,000,000 SEK
- SEK
3,270,000,000 SEK
- SEK
3,270,000,000 SEK
- SEK
- SEK
Profit (loss)
3,436,000,000 SEK
3,269,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.